XNAS
AVTE
Market cap2.72bUSD
Apr 28, Last price
93.80USD
Name
Aerovate Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.21%
Rev. gr., 5y
%
Revenues
0k
Net income
-70m
L-7.80%
CFO
-71m
L+25.39%
Profile
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 74,596 | 81,505 | 53,305 | |||
Unusual Expense (Income) | ||||||
NOPBT | (74,596) | (81,505) | (53,305) | |||
NOPBT Margin | ||||||
Operating Taxes | 55 | 56 | 25 | |||
Tax Rate | ||||||
NOPAT | (74,651) | (81,561) | (53,330) | |||
Net income | (69,628) -7.80% | (75,521) 46.61% | (51,511) 124.32% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 23,942 | 44,888 | 150 | |||
BB yield | -31.61% | -7.53% | -0.02% | |||
| Debt | ||||||
Debt current | 417 | 840 | 385 | |||
Long-term debt | 417 | 930 | 1,795 | |||
Deferred revenue | ||||||
Other long-term liabilities | 70 | 70 | 71 | |||
Net debt | (77,789) | (120,669) | (127,040) | |||
| Cash flow | ||||||
Cash from operating activities | (71,196) | (56,778) | (39,122) | |||
CAPEX | (142) | (195) | ||||
Cash from investing activities | 56,029 | 11,876 | 6,926 | |||
Cash from financing activities | 25,427 | 45,996 | 396 | |||
FCF | (73,964) | (81,218) | (53,847) | |||
| Balance | ||||||
Cash | 78,623 | 122,439 | 129,220 | |||
Long term investments | ||||||
Excess cash | 78,623 | 122,439 | 129,220 | |||
Stockholders' equity | (232,944) | (163,184) | (88,367) | |||
Invested Capital | 309,865 | 273,805 | 216,271 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 28,582 | 26,332 | 24,472 | |||
Price | 2.65 -88.29% | 22.63 -22.76% | 29.30 148.52% | |||
Market cap | 75,743 -87.29% | 595,885 -16.90% | 717,033 149.14% | |||
EV | (2,046) | 475,216 | 589,993 | |||
EBITDA | (74,314) | (81,409) | (53,237) | |||
EV/EBITDA | 0.03 | |||||
Interest | 1,751 | |||||
Interest/NOPBT | ||||||